Advertisement

Cancer Immunology, Immunotherapy

, Volume 62, Issue 2, pp 337–345 | Cite as

DNA methylation at promoter regions of interleukin 1B, interleukin 6, and interleukin 8 in non-small cell lung cancer

  • Xavier Tekpli
  • Nina E. Landvik
  • Kristine H. Anmarkud
  • Vidar Skaug
  • Aage Haugen
  • Shanbeh ZienolddinyEmail author
Original article

Abstract

Epidemiologic and experimental evidences support the concept that inflammation promotes the development and progression of cancers. Interleukins (ILs) regulate the expression of several molecules and signaling pathways involved in inflammation. High expression of some ILs in the tumor microenvironment has been associated with a more virulent tumor phenotype. To examine the role of IL-1β, IL-6, and IL-8 in non-small cell lung cancer, we measured mRNA levels and promoter DNA methylation in a panel of cultured human lung cells (n = 23) and in matched pair lung tumor versus adjacent non-tumorous tissues (n = 24). We found that lung cancer cells or tissues had significantly different DNA methylation and mRNA levels than normal human bronchial epithelial cells or adjacent non-tumorous tissues, respectively. High DNA methylation of ILs promoters in lung cancer cells or tissues was associated with low mRNA levels. We found an inverse correlation between DNA methylation of IL1B, IL6, and IL8 gene promoters and their corresponding mRNA levels, such inverse correlation was more significant for IL1B (i.e., all cancer cell lines used in this study had a hypermethylated IL1B promoter which was associated with silencing of the gene). Our results underline for the first time the role of epigenetic modifications in the regulation of the expression of key cytokines involved in the inflammatory response during lung cancer development.

Keywords

Interleukins DNA methylation Inflammation Lung carcinogenesis Epigenetic 

Notes

Acknowledgments

The authors gratefully acknowledge Dr Lodve Stangeland, Haukeland University Hospital, Bergen for recruiting the lung cancer patients. Dr Steen Mollerup is acknowledged for providing primary human lung epithelial cells. We are grateful to Mrs Tove Andreassen and Mrs Elin Einarsdottir Thorner for excellent technical assistance. This work was supported by the Norwegian Cancer Society.

Conflict of interest

None declared.

Supplementary material

262_2012_1340_MOESM1_ESM.pdf (387 kb)
Supplementary material 1 (PDF 386 kb)

References

  1. 1.
    Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674PubMedCrossRefGoogle Scholar
  2. 2.
    Hussain SP, Harris CC (2007) Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 121:2373–2380PubMedCrossRefGoogle Scholar
  3. 3.
    Godschalk R, Nair J, van Schooten FJ, Risch A, Drings P, Kayser K, Dienemann H, Bartsch H (2002) Comparison of multiple DNA adduct types in tumor adjacent human lung tissue: effect of cigarette smoking. Carcinogenesis 23:2081–2086PubMedCrossRefGoogle Scholar
  4. 4.
    Fitzpatrick FA (2001) Inflammation, carcinogenesis and cancer. Int Immunopharmacol 1:1651–1667PubMedCrossRefGoogle Scholar
  5. 5.
    Schetter AJ, Heegaard NHH, Harris CC (2010) Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 31:37–49PubMedCrossRefGoogle Scholar
  6. 6.
    Lewis AM, Varghese S, Xu H, Alexander HR (2006) Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med 4:48PubMedCrossRefGoogle Scholar
  7. 7.
    Apte RN, Voronov E (2008) Is interleukin-1 a good or bad ‘guy’ in tumor immunobiology and immunotherapy? Immunol Rev 222:222–241PubMedCrossRefGoogle Scholar
  8. 8.
    Elaraj DM, Weinreich DM, Varghese S, Puhlmann M, Hewitt SM, Carroll NM, Feldman ED, Turner EM, Alexander HR (2006) The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin Cancer Res 12:1088–1096PubMedCrossRefGoogle Scholar
  9. 9.
    Voronov E, Carmi Y, Apte RN (2007) Role of IL-1-mediated inflammation in tumor angiogenesis. Adv Exp Med Biol 601:265–270PubMedCrossRefGoogle Scholar
  10. 10.
    Cahill CM, Rogers JT (2008) Interleukin (IL) 1beta induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase-dependent AKT/IkappaB kinase alpha pathway targeting activator protein-1. J Biol Chem 283:25900–25912PubMedCrossRefGoogle Scholar
  11. 11.
    Brat DJ, Bellail AC, Van Meir EG (2005) The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol 7:122–133PubMedCrossRefGoogle Scholar
  12. 12.
    Xie K (2001) Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 12:375–391PubMedCrossRefGoogle Scholar
  13. 13.
    Trikha M, Corringham R, Klein B, Rossi JF (2003) Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 9:4653–4665PubMedGoogle Scholar
  14. 14.
    De Vita F, Orditura M, Auriemma A, Infusino S, Roscigno A, Catalano G (1998) Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol Rep 5:649–652PubMedGoogle Scholar
  15. 15.
    Campa D, Zienolddiny S, Maggini V, Skaug V, Haugen A, Canzian F (2004) Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis 25:229–235PubMedCrossRefGoogle Scholar
  16. 16.
    Landvik NE, Hart K, Skaug V, Stangeland LB, Haugen A, Zienolddiny S (2009) A specific interleukin-1B haplotype correlates with high levels of IL1B mRNA in the lung and increased risk of non-small cell lung cancer. Carcinogenesis 30:1186–1192PubMedCrossRefGoogle Scholar
  17. 17.
    Hull J, Ackerman H, Isles K, Usen S, Pinder M, Thomson A, Kwiatkowski D (2001) Unusual haplotypic structure of IL8, a susceptibility locus for a common respiratory virus. Am J Hum Genet 69:413–419PubMedCrossRefGoogle Scholar
  18. 18.
    Terry CF, Loukaci V, Green FR (2000) Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 275:18138–18144PubMedCrossRefGoogle Scholar
  19. 19.
    Belinsky SA (2004) Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 4:707–717PubMedCrossRefGoogle Scholar
  20. 20.
    Lechner JF, Haugen A, McClendon IA, Pettis EW (1982) Clonal growth of normal adult human bronchial epithelial cells in a serum-free medium. In Vitro 18:633–642PubMedCrossRefGoogle Scholar
  21. 21.
    Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, Pollack J, Peyton M, Zou Y, Kurie JM, Dimaio JM et al (2004) Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 64:9027–9034PubMedCrossRefGoogle Scholar
  22. 22.
    Oie HK, Russell EK, Carney DN, Gazdar AF (1996) Cell culture methods for the establishment of the NCI series of lung cancer cell lines. J Cell Biochem Suppl 24:24–31PubMedCrossRefGoogle Scholar
  23. 23.
    Tekpli X, Zienolddiny S, Skaug V, Stangeland L, Haugen A, Mollerup S (2012) DNA methylation of the CYP1A1 enhancer is associated with smoking-induced genetic alterations in human lung. Int J Cancer 131:1509–1516PubMedCrossRefGoogle Scholar
  24. 24.
    Hashimoto K, Oreffo RO, Gibson MB, Goldring MB, Roach HI (2009) DNA demethylation at specific CpG sites in the IL1B promoter in response to inflammatory cytokines in human articular chondrocytes. Arthritis Rheum 60:3303–3313PubMedCrossRefGoogle Scholar
  25. 25.
    Hartnett L, Egan LJ (2012) Inflammation, DNA methylation and colitis-associated cancer. Carcinogenesis 33:723–731PubMedCrossRefGoogle Scholar
  26. 26.
    Nile CJ, Read RC, Akil M, Duff GW, Wilson AG (2008) Methylation status of a single CpG site in the IL6 promoter is related to IL6 messenger RNA levels and rheumatoid arthritis. Arthritis Rheum 58:2686–2693PubMedCrossRefGoogle Scholar
  27. 27.
    Gasche JA, Hoffmann J, Boland CR, Goel A (2011) Interleukin-6 promotes tumorigenesis by altering DNA methylation in oral cancer cells. Int J Cancer 129:1053–1063PubMedCrossRefGoogle Scholar
  28. 28.
    Tischoff I, Wittekind C, Tannapfel A (2006) Role of epigenetic alterations in cholangiocarcinoma. J Hepatobiliary Pancreat Surg 13:274–279PubMedCrossRefGoogle Scholar
  29. 29.
    Hodge DR, Peng B, Cherry JC, Hurt EM, Fox SD, Kelley JA, Munroe DJ, Farrar WL (2005) Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res 65:4673–4682PubMedCrossRefGoogle Scholar
  30. 30.
    Vaissiere T, Sawan C, Herceg Z (2008) Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Res 659:40–48PubMedCrossRefGoogle Scholar
  31. 31.
    Jiang RQ, Deng L, Zhao L, Li XC, Zhang F, Xia YX, Gao Y, Wang XH, Sun BC (2011) miR-22 promotes HBV-related hepatocellular carcinoma development in males. Clin Cancer Res 17:5593–5603PubMedCrossRefGoogle Scholar
  32. 32.
    Wislez M, Philippe C, Antoine M, Rabbe N, Moreau J, Bellocq A, Mayaud C, Milleron B, Soler P, Cadranel J (2004) Upregulation of bronchioloalveolar carcinoma-derived C-X-C chemokines by tumor infiltrating inflammatory cells. Inflamm Res 53:4–12PubMedCrossRefGoogle Scholar
  33. 33.
    Portier M, Zhang XG, Ursule E, Lees D, Jourdan M, Bataille R, Klein B (1993) Cytokine gene expression in human multiple myeloma. Br J Haematol 85:514–520PubMedCrossRefGoogle Scholar
  34. 34.
    Ho CC, Liao WY, Wang CY, Lu YH, Huang HY, Chen HY, Chan WK, Chen HW, Yang PC (2008) TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer. Am J Respir Crit Care Med 177:763–770PubMedCrossRefGoogle Scholar
  35. 35.
    Qian BZ, Pollard JW (2010) Macrophage diversity enhances tumor progression and metastasis. Cell 141:39–51PubMedCrossRefGoogle Scholar
  36. 36.
    Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883–899PubMedCrossRefGoogle Scholar
  37. 37.
    Trevino V, Tadesse MG, Vannucci M, Al-Shahrour F, Antczak P, Durant S, Bikfalvi A, Dopazo J, Campbell MJ, Falciani F (2011) Analysis of normal-tumour tissue interaction in tumours: prediction of prostate cancer features from the molecular profile of adjacent normal cells. PLoS ONE 6:e16492PubMedCrossRefGoogle Scholar
  38. 38.
    Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, Voronov E (2006) The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 25:387–408PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Xavier Tekpli
    • 1
    • 2
  • Nina E. Landvik
    • 1
  • Kristine H. Anmarkud
    • 1
  • Vidar Skaug
    • 1
  • Aage Haugen
    • 1
  • Shanbeh Zienolddiny
    • 1
    Email author
  1. 1.Section for Toxicology, Department of Biological and Chemical Working EnvironmentNational Institute of Occupational HealthOsloNorway
  2. 2.Stem Cell GroupCenter for Molecular MedicineOsloNorway

Personalised recommendations